REFERENCES
- Campochiaro P A, Hackett S F. Ocular neovascularization: a valuable model system. Oncogene. 2003; 22: 6537–6548, [PUBMED], [INFOTRIEVE], [CSA]
- Gao G, Li Y, Gee S, et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem. 2002; 277: 9492–9497, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ozaki H, Seo M S, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000; 156: 697–707, [PUBMED], [INFOTRIEVE], [CSA]
- Adamis A P, Miller J W, Bernal M T, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445–450, [PUBMED], [INFOTRIEVE], [CSA]
- Aiello L P, Avery R L, Arrigg P G, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–1487, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Amin R H, Frank R N, Kennedy A, et al. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38: 36–47, [PUBMED], [INFOTRIEVE], [CSA]
- Murata T, Nakagawa K, Khalil A, et al. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 1996; 74: 819–825, [PUBMED], [INFOTRIEVE], [CSA]
- Sone H, Kawakami Y, Okuda Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997; 40: 726–730, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kvanta A, Algvere P V, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996; 37: 1929–1934, [PUBMED], [INFOTRIEVE], [CSA]
- Kliffen M, Sharma H S, Mooy C M, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81: 154–162, [PUBMED], [INFOTRIEVE], [CSA]
- Elbashir S M, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494–498, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Reich S J, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210–216, [PUBMED], [INFOTRIEVE], [CSA]
- Fire A, Xu S, Montgomery M K, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806–811, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kim B, Tang Q, Biswas P S, et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004; 165: 2177–2185, [PUBMED], [INFOTRIEVE], [CSA]
- Holzer M P, Solomon K D, Vroman D T, et al. Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 2954–2958, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cursiefen C, Masli S, Ng T F, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004; 45: 1117–1124, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- van Gool C A, Schuitmaker H J, Jager M J. Corneal neovascularization in rats as a model for photothrombotic therapy using bacteriochlorin a and an argon laser. Graefes Arch Clin Exp Ophthalmol. 1995; 233: 435–440, [PUBMED], [INFOTRIEVE], [CSA]
- Yi X, Ogata N, Komada M, et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol 1997; 235: 313–319, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lopez P F, Sippy B D, Lambert H M, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996; 37: 855–868, [PUBMED], [INFOTRIEVE], [CSA]
- Ishibashi T, Hata Y, Yoshikawa H, et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997; 235: 159–167, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gimbrone M A, Jr., Cotran R S, Leapman S B, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst. 1974; 52: 413–427, [PUBMED], [INFOTRIEVE], [CSA]
- Folkman J, Weisz P B, Joullie M M, et al. Control of angiogenesis with synthetic heparin substitutes. Science 1989; 243: 1490–1493, [PUBMED], [INFOTRIEVE], [CSA]
- Avery R L, Connor T B, Jr., Farazdaghi M. Systemic amiloride inhibits experimentally induced neovascularization. Arch Ophthalmol. 1990; 108: 1474–1476, [PUBMED], [INFOTRIEVE], [CSA]
- Murata M, Nakagawa M, Takahashi S. Inhibitory effects of plasminogen fragment on experimentally induced neovascularization of rat corneas. Graefes Arch Clin Exp Ophthalmol. 1997; 235: 584–586, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Senger D R, Galli S J, Dvorak A M, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983–985, [PUBMED], [INFOTRIEVE], [CSA]
- Leung D W, Cachianes G, Kuang W J, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–1309, [PUBMED], [INFOTRIEVE], [CSA]
- Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001; 26: 25–35, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tolentino M J, Miller J W, Gragoudas E S, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103: 1820–1828, [PUBMED], [INFOTRIEVE], [CSA]
- Adamis A P, Shima D T, Tolentino M J, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66–71, [PUBMED], [INFOTRIEVE], [CSA]
- Pierce E A, Avery R L, Foley E D, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 1995; 92: 905–909, [PUBMED], [INFOTRIEVE], [CSA]
- Tolentino M J, Miller J W, Gragoudas E S, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996; 114: 964–970, [PUBMED], [INFOTRIEVE], [CSA]
- Husain D, Ambati B, Adamis A P, Miller J W. Mechanisms of age-related macular degeneration. Ophthalmol Clin North Am. 2002; 15: 87–91, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Witmer A N, Vrensen G F, Van Noorden C J, Schlingemann R O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003; 22: 1–29, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kim I, Ryan A M, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999; 40: 2115–2121, [PUBMED], [INFOTRIEVE], [CSA]
- Kuroki M, Voest E E, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996; 98: 1667–1675, [PUBMED], [INFOTRIEVE], [CSA]
- Mousa S A, Lorelli W, Campochiaro P A. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J Cell Biochem. 1999; 74: 135–143, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wang B, Zou Y, Yuan Z L, Xiao J G. Genistein suppressed upregulation of vascular endothelial growth factor expression by cobalt chloride and hypoxia in rabbit retinal pigment epithelium cells. J Ocul Pharmacol Ther. 2003; 19: 457–464, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Punglia R S, Lu M, Hsu J, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 1997; 46: 1619–1626, [PUBMED], [INFOTRIEVE], [CSA]
- Wall N R, Shi Y. Small RNA: can RNA interference be exploited for therapy?. Lancet. 2003; 362: 1401–1403, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sledz C A, Williams B R. RNA interference and double-stranded-RNA-activated pathways. Biochem Soc Trans. 2004; 32: 952–956, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Murata M, Kador P F, Sato S. Vascular endothelial growth factor (VEGF) enhances the expression of receptors and activates mitogen-activated protein (MAP) kinase of dog retinal capillary endothelial cells. J Ocul Pharmacol Ther. 2000; 16: 383–391, [PUBMED], [INFOTRIEVE], [CSA]
- Sledz C A, Holko M, de Veer M J, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834–839, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999; 77: 527–543, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gerber H P, Malik A K, Solar G P, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954–958, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]